Candriam Luxembourg S.C.A. boosted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 123.7% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 98,345 shares of the medical equipment provider’s stock after buying an additional 54,390 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Zimmer Biomet Holdings were worth $12,628,000 as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in the stock. Baldwin Brothers Inc. MA acquired a new stake in Zimmer Biomet Holdings during the first quarter valued at approximately $1,671,000. Guild Investment Management Inc. bought a new position in Zimmer Biomet Holdings during the first quarter valued at $3,362,000. Alpha Windward LLC boosted its position in Zimmer Biomet Holdings by 1.1% in the first quarter. Alpha Windward LLC now owns 1,651 shares of the medical equipment provider’s stock valued at $202,000 after buying an additional 18 shares during the last quarter. Orrstown Financial Services Inc. boosted its position in Zimmer Biomet Holdings by 3.7% in the first quarter. Orrstown Financial Services Inc. now owns 11,123 shares of the medical equipment provider’s stock valued at $1,358,000 after buying an additional 399 shares during the last quarter. Finally, Kempner Capital Management Inc. boosted its stake in shares of Zimmer Biomet Holdings by 15.2% in the first quarter. Kempner Capital Management Inc. now owns 17,495 shares of the medical equipment provider’s stock worth $2,136,000 after buying an additional 2,310 shares in the last quarter. 82.84% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Zimmer Biomet Holdings, Inc. (NYSE ZBH) traded down 0.58% during midday trading on Thursday, hitting $112.42. The stock had a trading volume of 1,070,211 shares. The stock has a market capitalization of $22.73 billion, a price-to-earnings ratio of 32.02 and a beta of 1.20. The stock has a 50 day moving average price of $123.10 and a 200-day moving average price of $121.18. Zimmer Biomet Holdings, Inc. has a 52 week low of $95.63 and a 52 week high of $133.49.
Zimmer Biomet Holdings (NYSE:ZBH) last released its earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.10 by $0.02. Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The company had revenue of $1.95 billion during the quarter, compared to analyst estimates of $1.95 billion. During the same period in the prior year, the firm posted $2.02 EPS. Zimmer Biomet Holdings’s revenue was up 1.1% compared to the same quarter last year. Equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post $8.24 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Friday, September 22nd will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.85%. The ex-dividend date is Thursday, September 21st. Zimmer Biomet Holdings’s payout ratio is currently 27.59%.
COPYRIGHT VIOLATION NOTICE: This article was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://stocknewstimes.com/2017/08/17/candriam-luxembourg-s-c-a-increases-position-in-zimmer-biomet-holdings-inc-nysezbh-updated.html.
ZBH has been the subject of a number of research reports. Needham & Company LLC upped their target price on shares of Zimmer Biomet Holdings from $151.00 to $153.00 and gave the company a “strong-buy” rating in a report on Friday, April 28th. Oppenheimer Holdings, Inc. set a $132.00 target price on shares of Zimmer Biomet Holdings and gave the stock a “buy” rating in a research report on Friday, April 28th. Goldman Sachs Group, Inc. (The) started coverage on shares of Zimmer Biomet Holdings in a research note on Tuesday, May 16th. They issued a “sell” rating and a $92.00 target price on the stock. Wells Fargo & Company downgraded shares of Zimmer Biomet Holdings from an “outperform” rating to a “market perform” rating in a research note on Friday, April 28th. Finally, Zacks Investment Research cut shares of Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $136.90.
In related news, VP Tony W. Collins sold 16,986 shares of the business’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $121.74, for a total value of $2,067,875.64. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Sang Yi sold 17,731 shares of the stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $124.56, for a total transaction of $2,208,573.36. The disclosure for this sale can be found here. Insiders own 1.07% of the company’s stock.
About Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
